Published in final edited form as:

J Matern Fetal Neonatal Med. 2014 February ; 27(3): 217–227. doi:10.3109/14767058.2013.806906.

Maternal Plasma Soluble TRAIL is Decreased in Preeclampsia

Piya Chaemsathong, MD^{1,2}, Tinnakorn Chaiworapongsa, MD^{1,2}, Roberto Romero, MD, D. Med. Sci.¹, Steven J. Korzeniewski, PhD^{1,2}, Tamara Stampalija, MD^{1,2,3}, Nandor Gabor Than, MD, PhD^{1,2}, Zhong Dong, MD, PhD¹, Jezid Miranda, MD¹, Lami Yeo, MD^{1,2}, and Sonia S Hassan, MD^{1,2}

¹Perinatology Research Branch, NICHD/NIH/DHHS, Bethesda, Maryland and Detroit, Michigan, USA

²Wayne State University School of Medicine, Department of Obstetrics and Gynecology, Detroit, Michigan, USA

³Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy

Abstract

Objective—Preeclampsia (PE) is characterized by systemic intravascular inflammation. Women who develop PE are at an increased risk for cardiovascular disease in later life. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has anti-atherosclerotic effects in endothelial cells and can mediate neutrophil apoptosis. Low soluble TRAIL (sTRAIL) and high C-reactive protein (CRP) concentrations are associated with an increased risk of future cardiovascular disease in non-pregnant individuals. The aim of this study was to determine whether maternal plasma concentrations of sTRAIL and CRP differ between women with PE and those with uncomplicated pregnancies.

Methods—This cross-sectional study included women with an uncomplicated pregnancy (n=93) and those with PE (n=52). Maternal plasma concentrations of sTRAIL and CRP concentrations were determined by ELISA.

Results—1) The median plasma sTRAIL concentration (pg/mL) was significantly lower and the median plasma CRP concentration was significantly higher in women with PE than in those with an uncomplicated pregnancy (25.55 vs. 29.17; p = 0.03 and 8.0 vs. 4.1; p=0.001, respectively); 2) the median plasma concentration sTRAIL/CRP ratio was twofold lower in women with PE than in those with an uncomplicated pregnancy (p<0.001); and 3) women with plasma sTRAIL and CRP ratio in the lowest quartile were eight times more likely to have PE than women with concentrations in the upper three quartiles (OR 8.9; 95% CI: 2.8–27.8).

Conclusion—Maternal plasma sTRAIL concentrations are lower (while those of CRP are higher) in women with PE than in those with uncomplicated pregnancies. These findings are consistent with the evidence of intravascular inflammation in this disorder.

Address correspondence to: Roberto Romero, MD, D. Med. Sci. Perinatology Research Branch, NICHD, NIH, DHHS Wayne State University/Hutzel Women's Hospital 3990 John R, Box 4, Detroit, MI 48201, USA Telephone: (313) 993-2700 Fax: (313) 993-2694 romeror@mail.nih.gov.

Presented at the 33rd Annual Meeting Society for Maternal-Fetal Medicine, February 11–16, 2013, San Francisco, CA, USA

Declaration of Interest The authors report no declarations of interest.

Keywords

apoptosis; coronary artery disease; C-reactive protein; endothelial cell; intravascular inflammation; neutrophil apoptosis

Introduction

Preeclampsia (PE) is a multisystemic disorder defined clinically by the combination of new onset of gestational hypertension and proteinuria (1–16). The condition has been termed “toxemia of pregnancy” because soluble factors have been implicated in its pathophysiology (1, 17–20). A disorder of deep placentation (21–26), resulting in failure of physiologic transformation of the spiral arteries has been proposed to lead to uteroplacental ischemia (27–29), which in turn, leads to the disease.

Intravascular inflammation (30–34) and endothelial cell dysfunction (33, 35–45) are characteristic of PE, although intravascular inflammation has been reported in patients with other complications of pregnancy, such as preterm labor (46–48), preterm premature rupture of membrane (PROM) (49, 50), and small for gestational age (SGA) (51–65); failure of physiologic transformation of the spiral arteries has also been described in these three conditions (21, 66–68). A subset of patients with PE demonstrates an anti-angiogenic state. Plasma concentrations of the angiogenic factor [placental growth factor (PlGF)], are decreased (69–78), and the anti-angiogenic factors [soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), soluble endoglin (sEng)] are elevated both prior to (79–89) and at the time of the diagnosis (90–97). Moreover, the concentration of these factors can be used to predict the outcome of the disease in patients presented to the obstetrical triage area (98–101).

Women who develop PE are at an increased risk of cardiovascular disease in later life (102–112). There are common risk factors for both conditions, such as hyperlipidemia (113–120), insulin resistance (113, 114, 119, 121–123), obesity (113, 114, 120, 124), and hypertension (113, 114, 120). This suggests that an underlying mechanism of disease may predispose to both PE and cardiovascular disease. C-reactive protein (CRP) is a positive acute phase reactant protein that is produced by the liver in response to pro-inflammatory cytokines (125–127), and has pro-inflammatory and pro-atherogenic properties (128–134). A solid body of evidence has shown that CRP is a major predictor of the subsequent risk of cardiovascular disease in non-pregnant subjects (135–148). CRP is also known to be elevated in women with PE before (60, 149–153) and at the time of diagnosis (154–158).

Tumor Necrosis Factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL), a type II membrane bound tumor necrosis factor (TNF) family ligand (159, 160), is a cytokine capable of inducing apoptosis. It has both anti-atherosclerotic and anti-inflammatory properties, and possibly promotes survival and proliferation of human vascular endothelial cells (161–166). TRAIL has been implicated in the resolution of inflammation by removing both senescent circulating and activated tissue neutrophils (167–169).

While prior studies have reported that soluble TRAIL (sTRAIL) concentrations are reduced in the setting of cardiovascular disease (166, 170–173), there is a paucity of information about the behavior of sTRAIL in pregnancy and PE (174). The aim of this study was to determine whether maternal plasma sTRAIL concentrations differ between uncomplicated pregnancies and PE at the time of diagnosis.

Materials and methods

Study design

A cross-sectional study was conducted by searching the clinical database and bank of biologic samples of Wayne State University, Detroit Medical Center and the Perinatology Research Branch. The following group were included: 1) women with uncomplicated pregnancies (n = 93); and 2) women with PE (n = 52). Women with multiple gestations, affected by medical conditions (e.g. chronic hypertension, diabetes, renal disease), and those carrying fetus with congenital anomalies were excluded. All patients were enrolled at Hutzel Women's Hospital, Detroit, MI, USA and had venipuncture between 20 and 42 weeks.

PE was defined as hypertension (systolic blood pressure $\geq$ 140 mmHg or diastolic blood pressure $\geq$ 90 mmHg on at least two occasions, 4 hours to 1 week apart) and proteinuria ($\geq$ 300 milligrams in a 24-hour urine collection or one urine dipstick measurement $\geq$ 2+) (175). Severe PE was defined as previously describe (175). Patients with PE were also sub classified as preterm ($<$ 37 weeks) and term ($\geq$ 37 weeks) according to the gestational age at diagnosis. Small for gestational age (SGA) was defined by ultrasonographic estimated fetal weight and birthweight $<$ 10th percentile for gestational age, according to the reference range proposed by Alexander et al (176, 177).

Women with an uncomplicated pregnancy were enrolled from either the Labor and Delivery unit (in cases of scheduled cesarean delivery) or the antenatal clinic, and were followed until the time of delivery. Uncomplicated pregnancy was defined as: (1) no medical, obstetrical, or surgical complications; (2) absence of labor at the time of venipuncture; and (3) delivery of a normal term ($\geq$ 37 weeks) infant whose birthweight was between the 10th and 90th percentile for gestational age. All women provided informed consent prior to the collection of plasma samples. The collection and utilization of samples for research purposes was approved by the Human Investigation Committee of Wayne State University and the IRB of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, NIH, DHHS. Many of these samples were used previously in studies of intravascular inflammation, soluble adhesion molecules, and cytokine biology in uncomplicated and complicated pregnancies.

Sample collection and human sTRAIL and CRP

Venipuncture was performed in the antenatal clinic or in the Labor and Delivery unit for women with uncomplicated pregnancies at the time of diagnosis for women with PE. Blood was collected into tubes containing EDTA, centrifuged, and stored at -70°C .

Concentrations of sTRAIL were measured using enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN, USA). This assay employs the quantitative

sandwich immunoassay technique. Briefly, recombinant human TRAIL standards and maternal plasma specimens were incubated in duplicate wells of the microtiter plates, which were pre-coated with monoclonal antibodies specific for TRAIL. During incubation, immobilized antibodies in the microtiter plate bound TRAIL which was present in both the standard and sample groups. After washing unbound substances, polyclonal antibodies to human TRAIL conjugated to an enzyme (horse-radish peroxidase) were added to the assay wells. Once the incubation period was complete, assay plates were washed to remove unbound antibody-enzyme reagents. Upon addition of a substrate solution (tetramethylbenzidine), color developed in the assay plates proportionally to the amount of TRAIL bound in the initial step. Microtiter plates were read using a programmable spectrophotometer (SpectraMax M5 Multi-Mode Microplate Reader, Molecular Devices, Sunnyvale, CA USA). The inter-and intra-assay coefficients of variation were 6.5% and 3.7%, respectively. The lowest maternal plasma sTRAIL concentration detectable was 8.2 pg/mL. Maternal plasma concentrations of CRP were also determined in 85 patients. For CRP, the inter-and intra-assay coefficients of variation were 10.66% and 2.96%, respectively. The lowest maternal plasma CRP concentration detectable was 0.048 ng/mL.

Statistical analysis

Normality of arithmetic data was assessed using the Kolmogorov-Smirnov test and visual plot inspection. Differences in frequency distributions of categorical variables were tested using the Chi-square or Fisher's exact test, where appropriate. Bivariate comparisons of arithmetic data were examined using a Mann-Whitney U test in the presence of non-normally distributions. Multivariable general linear models were constructed to explore the effect of potentially confounding factors, selected based upon clinical knowledge (gestational age at venipuncture, maternal age, nulliparity, and race). These were entered into a 'full model', and variable reduction was considered to derive a 'final model' based on the plausibility of regression coefficients, association between independent variables, and the magnitude of change in the association between study group and group least squares geometric mean sTRAIL concentrations. Examined analytes were logarithmically transformed (base 2) to better meet the assumptions of linear regression. Multivariable logistic regression models were used to determine the magnitude of association between study group and the ratio of plasma sTRAIL/CRP, dichotomized as +/- as above or below the first lowest quartile value calculated among patients with an uncomplicated pregnancy. Spearman correlation coefficients were also used to characterize the relationship between plasma concentrations of sTRAIL and CRP in each group. Statistical analysis was performed using SPSS 19 (IBM Corp, Armonk, NY) and SAS 9.3 (Cary, NC). A p value < 0.05 was considered statistically significant.

Results

Demographic, clinical and obstetric characteristics are displayed in Table 1. The frequency of nulliparous women was greater in the women with PE than in those with an uncomplicated pregnancy. Otherwise, there were no significant differences in characteristics between study groups ($p > 0.05$).

In women with PE, the median plasma sTRAIL concentration was significantly lower while that of CRP was significantly higher than in those with uncomplicated pregnancies ($p=0.03$ and 0.001 , respectively) (Figure 1). Pre-specified subgroup analyses suggest that these differences may be confined to women with PE examined at <37 weeks of gestation. For this group, the median plasma sTRAIL concentration was 19% lower and the median CRP concentration was 53% greater than in those with uncomplicated pregnancies ($p=0.03$ and 0.002 , respectively) (Figure 2). There were no significant differences in the median plasma sTRAIL and CRP concentrations between women with uncomplicated pregnancy at term and PE at term (Figure 3).

Multivariable adjustment for gestational age at venipuncture, maternal age, nulliparity, and race revealed that none of these factors were independently associated with plasma concentration of sTRAIL or CRP. The relationship between study group and either analyte also did not vary significantly as a function of gestational age at venipuncture ($p > 0.34$). Adjustment for BMI changed the group least squares means by less than 2%, and did not alter the statistical significance. Thus, the relationship between study group and either analyte was not confounded by any of the examined factors.

Among women with uncomplicated pregnancies, the plasma sTRAIL concentration was not correlated with plasma CRP concentrations (spearman correlation = 0.13 ; $p=0.30$). Alternatively, among women with PE, plasma sTRAIL concentrations were negatively correlated with plasma CRP concentrations (spearman correlation = -0.28); however, the relationship did not reach the statistical significance ($p=0.10$).

The plasma sTRAIL/CRP ratio demonstrated a greater magnitude of the difference between PE and uncomplicated pregnancy than either analyte individually. Specifically, the median ratio was approximately twofold lower in women with PE than in those with an uncomplicated pregnancy ($p<0.001$) (Figure 4). Women with a plasma sTRAIL/CRP ratio in the lowest quartile were eightfold more likely to have PE than in women with concentrations in the upper three quartiles [OR 8.0 ; 95% Confidence Interval (CI): $2.9-22.4$]. Multivariable adjustment for maternal age, nulliparity, race, and gestational age at venipuncture slightly increased the magnitude of this association (OR 8.9 ; 95% CI: $2.8-27.8$). Adjusting for BMI did not change the magnitude of association between PE and the lowest quartile ratio (OR 7.4 ; 95% CI: $2.0-26.1$).

Discussion

Principal findings

1) women with PE had a significantly lower median plasma sTRAIL, sTRAIL/CRP ratio concentration, and higher median CRP concentration than in those with uncomplicated pregnancies; 2) there was no correlation between plasma concentrations of sTRAIL and CRP; and 3) women with a median plasma sTRAIL/CRP ratio in the lowest quartile were eight times more likely to have PE than in those with concentrations in the upper three quartiles.

Potential mechanisms by which decreased plasma sTRAIL concentrations may confer an increased risk of PE are its anti-inflammatory and anti-atherosclerotic effects in endothelial cells and its involvement in systemic intravascular inflammation (167–169).

Biology of TRAIL

TRAIL interacts with four high-affinity transmembrane receptors and one soluble receptor belonging to the TNF receptor family. TRAIL-receptor 1 (TRAIL-R1)/Death receptor 4 (DR4) (178) and TRAIL-R2/DR5 (179–182) are capable of inducing a pro-apoptotic signal through: 1) intracellular death domain (DD), which; in turn recruits procaspase-8 to activate death-inducing signaling complex (DISC), followed by the cleavage and activation of effector caspases 3, 6 and 7 (so called extrinsic or mitochondrial independent pathways) (183–186); and 2) activation of Bcl-2 interacting protein domain (BID) by the engagement of mitochondria (so called the intrinsic pathway) (187, 188). In contrast, binding of TRAIL to TRAIL-R3/Decoy receptor 1 (DcR1) (179, 180, 182, 189, 190) or TRAIL-R4/DcR2 (189, 190) cannot induce an apoptotic signal, and thus, both are considered decoy receptors. TRAIL can also bind to osteoprotegerin (OPG), a protein involved in bone remodeling which acts through ligands other than TRAIL (191, 192). The soluble form of TRAIL also elicits apoptosis signals similar to that of the cell surface TRAIL (193, 194).

TRAIL and its receptors are expressed in a variety of human tissues, most predominantly in immune cells (e.g. lymphocytes, monocytes, dendritic cells, natural killer cells, neutrophils, macrophages) (159, 167, 179, 182, 189, 195), human endothelial cells (60, 75), the placenta, and fetal membranes (196, 197). The proposed functions of TRAIL in pregnancy are to establish immune tolerance at the feto-maternal interface (196, 197) and induce smooth muscle cell apoptosis in the spiral arteries (198, 199).

TRAIL is capable of inducing apoptosis in macrophages and neutrophils, therefore, a disturbance in this process may result in prolonged neutrophil survival, and contribute to a further systemic inflammatory response and possible multiple organs dysfunction (167, 195) (200). The anti-inflammatory and anti-atherosclerotic properties of TRAIL are demonstrated by the down-regulation of proadhesive inflammatory cytokines (CCL8, CXCL10) in models of human endothelial cell culture (165). Systemic TRAIL administration also markedly reduce the development and extension of atherosclerotic plaques in apolipoprotein E-null diabetics mice by inducing macrophage and neutrophil cell death (195, 201, 202), and increasing vascular smooth muscle cell content (201). TRAIL modulates the production of prostaglandin E₂ (PGE₂), prostaglandin I₂ (PGI₂) and nitric oxide (NO) (162). Such factors regulate vascular tone, promote endothelial cell survival and migration, inhibit platelet adhesion and aggregation, and inhibit leukocyte adherence, supporting the antithrombotic and anti-inflammatory effects of TRAIL in endothelial cells (162–164). Moreover, TRAIL and ApoE-deficient mice have a significantly greater mean area of atheromatous lesions in the aorta than ApoE-deficient mice controls when fed with a regular chow or western diet for 8 weeks (203). Taken all together, TRAIL is a protective cytokine against inflammation and also has a protective role in vascular endothelial cells.

Maternal Plasma sTRAIL, CRP concentrations in patients with preeclampsia

In the study reported herein, women with PE had a significantly lower median plasma sTRAIL concentration than in those with uncomplicated pregnancies. The decrease in plasma sTRAIL concentrations in patients with PE may be associated with prolonged neutrophil survival, and thus, an enhanced systemic inflammatory response.

Zauli *et al* (174) reported no significant differences in maternal serum sTRAIL concentrations at 12 weeks of gestation between patients with uncomplicated pregnancies and those who subsequently developed hypertensive disorders of pregnancy (174). The apparent discrepancy can be explained by differences in the timing of venipuncture, or methodological differences (including variation in study population and laboratory methods). The observation that CRP concentrations are higher in women with PE than in those with uncomplicated pregnancies at the time of diagnosis is consistent with previous studies (60, 149–158), and may partly explain prior observations that patients with PE are at an increased risk of cardiovascular events in later life (102–112).

Taken together, our findings suggest that the lower maternal plasma concentration of sTRAIL and the sTRAIL/CRP ratio in women with PE may reflect an exaggerated intravascular inflammatory response in such patients. However, further investigation is necessary to determine whether this finding is a reflection of the severity of inflammation or is specific to PE. Moreover, lower plasma sTRAIL concentrations and higher plasma CRP concentrations in women with PE may be contributing factors to future cardiovascular disease in these women.

Strengths and limitations

This is the first study to evaluate plasma concentrations of sTRAIL and CRP in women with uncomplicated pregnancies and those with PE. Due to the cross-sectional design, temporal relationships between sTRAIL, CRP and the clinical diagnosis of preeclampsia could not be established.

Conclusions

Among women with PE, maternal plasma sTRAIL concentrations are lower, while those of CRP are higher than in those with uncomplicated pregnancies. These findings are consistent with the presence of intravascular inflammation in women with PE.

Acknowledgments

This research was supported, in part, by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH); and, in part, with Federal funds from NICHD, NIH under Contract No. HHSN275201300006C.

References

1. Romero R, Lockwood C, Oyarzun E, Hobbins JC. Toxemia: new concepts in an old disease. *Seminars in perinatology*. 1988; 12(4):302–23. Epub 1988/10/01. [PubMed: 3065943]
2. Romero R. Prenatal medicine: the child is the father of the man. 1996. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine*, the

- Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2009; 22(8):636–9. Epub 2009/09/09.
3. Redman CW. Preeclampsia: a multi-stress disorder. *La Revue de medecine interne / fondee par la Societe nationale francaise de medecine interne*. 2011; 32(Suppl 1):S41–4. Epub 2011/05/03. [PubMed: 21530020]
 4. Roberts JM, Gammill HS. Preeclampsia: recent insights. *Hypertension*. 2005; 46(6):1243–9. Epub 2005/10/19. [PubMed: 16230510]
 5. Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. *American journal of obstetrics and gynecology*. 2011; 205(3):191–8. Epub 2011/11/11. [PubMed: 22071049]
 6. Barton JR, Sibai BM. Acute life-threatening emergencies in preeclampsia--eclampsia. *Clinical obstetrics and gynecology*. 1992; 35(2):402–13. Epub 1992/06/01. [PubMed: 1638831]
 7. Than NG, Romero R, Hillermann R, Cozzi V, Nie G, Huppertz B. Prediction of preeclampsia - a workshop report. *Placenta*. 2008; 29(Suppl A):S83–5. Epub 2007/12/07. [PubMed: 18061661]
 8. Romero R, Vizado J, Emamian M, Duffy T, Riely C, Halford T, et al. Clinical significance of liver dysfunction in pregnancy-induced hypertension. *American journal of perinatology*. 1988; 5(2):146–51. Epub 1988/04/01. [PubMed: 3348861]
 9. Di Renzo GC. The great obstetrical syndromes. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2009; 22(8):633–5. Epub 2009/09/09.
 10. von Dadelszen P, Magee LA. Hypertensive disease in pregnancy. Preface. *Best practice & research Clinical obstetrics & gynaecology*. 2011; 25(4):389–90. Epub 2011/04/30. [PubMed: 21527239]
 11. Romero R, Duffy TP. Platelet disorders in pregnancy. *Clinics in perinatology*. 1980; 7(2):327–48. Epub 1980/09/01. [PubMed: 7002423]
 12. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. *Science*. 2005; 308(5728):1592–4. Epub 2005/06/11. [PubMed: 15947178]
 13. Redman CW, Sargent IL. Preeclampsia and the systemic inflammatory response. *Seminars in nephrology*. 2004; 24(6):565–70. Epub 2004/11/06. [PubMed: 15529291]
 14. Payne B, Magee LA, von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. *Best practice & research Clinical obstetrics & gynaecology*. 2011; 25(4):449–62. Epub 2011/04/05. [PubMed: 21459048]
 15. Dietl J. The pathogenesis of pre-eclampsia: new aspects. *Journal of perinatal medicine*. 2000; 28(6):464–71. Epub 2001/01/13. [PubMed: 11155433]
 16. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet*. 2010; 376(9741):631–44. Epub 2010/07/06. [PubMed: 20598363]
 17. Hofbauer J. The evolution of the biologic concept of the etiology of late toxemia. *American journal of obstetrics and gynecology*. 1946; 51:514–8. Epub 1946/04/01. [PubMed: 21023754]
 18. Theobald GW. The toxæmias of pregnancy. *The Journal of obstetrics and gynaecology of the British Empire*. 1946; 53:17–41. Epub 1946/02/01. [PubMed: 21017090]
 19. Page NM, Lowry PJ. Is 'pre-eclampsia' simply a response to the side effects of a placental tachykinin? *The Journal of endocrinology*. 2000; 167(3):355–61. Epub 2000/12/15. [PubMed: 11115762]
 20. Page NM, Woods RJ, Gardiner SM, Lomthaisong K, Gladwell RT, Butlin DJ, et al. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. *Nature*. 2000; 405(6788):797–800. Epub 2000/06/24. [PubMed: 10866201]
 21. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. *American journal of obstetrics and gynecology*. 2011; 204(3):193–201. Epub 2010/11/26. [PubMed: 21094932]
 22. Pijnenborg, R.; Brosens, I.; Romero, R. *Placental bed disorders*. Cambridge University Press; United States of America: 2010.
 23. Brosens IA. Morphological changes in the utero-placental bed in pregnancy hypertension. *Clinics in obstetrics and gynaecology*. 1977; 4(3):573–93. Epub 1977/12/01. [PubMed: 598186]

24. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. *American journal of obstetrics and gynecology*. 2002; 187(5):1416–23. Epub 2002/11/20. [PubMed: 12439541]
25. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. *British journal of obstetrics and gynaecology*. 1991; 98(7):648–55. Epub 1991/07/01. [PubMed: 1883787]
26. Robertson WB, Brosens I, Dixon G. Maternal uterine vascular lesions in the hypertensive complications of pregnancy. *Perspectives in nephrology and hypertension*. 1976; 5:115–27. Epub 1976/01/01. [PubMed: 1005030]
27. Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. *Journal of perinatal medicine*. 2011; 39(6):641–52. Epub 2011/08/19. [PubMed: 21848483]
28. George EM, Granger JP. Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. *Hypertension*. 2012; 60(2):507–11. Epub 2012/05/09. [PubMed: 22566502]
29. Gilbert JS, Ryan MJ, LaMarca BB, Sedek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. *American journal of physiology Heart and circulatory physiology*. 2008; 294(2):H541–50. Epub 2007/12/07. [PubMed: 18055511]
30. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. *American journal of obstetrics and gynecology*. 1998; 179(1):80–6. Epub 1998/08/15. [PubMed: 9704769]
31. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. *American journal of obstetrics and gynecology*. 1999; 180(2 Pt 1):499–506. Epub 1999/02/13. [PubMed: 9988826]
32. Naccasha N, Gervasi MT, Chaiworapongsa T, Berman S, Yoon BH, Maymon E, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. *American journal of obstetrics and gynecology*. 2001; 185(5):1118–23. Epub 2001/11/22. [PubMed: 11717644]
33. Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, et al. Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2002; 12(1):19–27. Epub 2002/11/09.
34. Sibai B, Romero R, Klebanoff MA, Rice MM, Caritis S, Lindheimer MD, et al. Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. *American journal of obstetrics and gynecology*. 2009; 200(6):630, e1–8. Epub 2009/03/25. [PubMed: 19306961]
35. Cindrova-Davies T. Gabor Than Award Lecture 2008: pre-eclampsia - from placental oxidative stress to maternal endothelial dysfunction. *Placenta*. 2009; 30(Suppl A):S55–65. Epub 2009/01/03. [PubMed: 19118896]
36. Friedman SA, Schiff E, Emeis JJ, Dekker GA, Sibai BM. Biochemical corroboration of endothelial involvement in severe preeclampsia. *American journal of obstetrics and gynecology*. 1995; 172(1 Pt 1):202–3. Epub 1995/01/01. [PubMed: 7847535]
37. Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. *Reviews of reproduction*. 1996; 1(2):107–16. Epub 1996/05/01. [PubMed: 9414447]
38. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. *Placenta*. 2009; 30(Suppl A):S32–7. Epub 2008/12/17. [PubMed: 19070896]
39. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. *American journal of obstetrics and gynecology*. 1989; 161(5):1200–4. Epub 1989/11/01. [PubMed: 2589440]
40. Roberts JM, Taylor RN, Goldfien A. Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia. *American journal of hypertension*. 1991; 4(8):700–8. Epub 1991/08/01. [PubMed: 1930853]

41. Roberts JM. Endothelial dysfunction in preeclampsia. *Seminars in reproductive endocrinology*. 1998; 16(1):5–15. Epub 1998/07/09. [PubMed: 9654603]
42. Taylor RN, de Groot CJ, Cho YK, Lim KH. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. *Seminars in reproductive endocrinology*. 1998; 16(1):17–31. Epub 1998/07/09. [PubMed: 9654604]
43. Petrozella L, Mahendroo M, Timmons B, Roberts S, McIntire D, Alexander JM. Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. *American journal of obstetrics and gynecology*. 2012; 207(2):140, e20–6. Epub 2012/07/31. [PubMed: 22840727]
44. Dekker GA, van Geijn HP. Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; therapeutic perspectives. *Journal of perinatal medicine*. 1996; 24(2):119–39. Epub 1996/01/01. [PubMed: 8773939]
45. Dekker GA, van Geijn HP. Endothelial dysfunction in preeclampsia. Part I: Primary prevention. Therapeutic perspectives. *Journal of perinatal medicine*. 1996; 24(2):99–117. Epub 1996/01/01. [PubMed: 8773938]
46. Gervasi MT, Chaiworapongsa T, Naccasha N, Blackwell S, Yoon BH, Maymon E, et al. Phenotypic and metabolic characteristics of maternal monocytes and granulocytes in preterm labor with intact membranes. *American journal of obstetrics and gynecology*. 2001; 185(5):1124–9. Epub 2001/11/22. [PubMed: 11717645]
47. Gotsch F, Romero R, Erez O, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, et al. The preterm parturition syndrome and its implications for understanding the biology, risk assessment, diagnosis, treatment and prevention of preterm birth. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.* 2009; 22(Suppl 2):5–23. Epub 2009/12/03.
48. Gotsch F, Romero R, Kusanovic JP, Erez O, Espinoza J, Kim CJ, et al. The anti-inflammatory limb of the immune response in preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: a role for interleukin-10. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.* 2008; 21(8):529–47. Epub 2008/07/09.
49. Gervasi MT, Chaiworapongsa T, Naccasha N, Pacora P, Berman S, Maymon E, et al. Maternal intravascular inflammation in preterm premature rupture of membranes. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.* 2002; 11(3):171–5. Epub 2002/10/17.
50. Loukovaara MJ, Alfthan HV, Kurki MT, Hiilesmaa VK, Andersson SH. Serum highly sensitive C-reactive protein in preterm premature rupture of membranes. *European journal of obstetrics, gynecology, and reproductive biology*. 2003; 110(1):26–8. Epub 2003/08/23.
51. Ogge G, Romero R, Chaiworapongsa T, Gervasi MT, Pacora P, Erez O, et al. Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.* 2010; 23(6):476–87. Epub 2009/11/18.
52. Kusanovic JP, Romero R, Hassan SS, Gotsch F, Edwin S, Chaiworapongsa T, et al. Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet.* 2007; 20(12):867–78. Epub 2007/09/14.
53. Labarrere C, Manni J, Salas P, Althabe O. Intrauterine growth retardation of unknown etiology. I. Serum complement and circulating immune complexes in mothers and infants. *American journal of reproductive immunology and microbiology : AJRIM*. 1985; 8(3):87–93. Epub 1985/07/01. [PubMed: 4025671]

54. Labarrere CA, Althabe OH. Intrauterine growth retardation of unknown etiology: II. Serum complement and circulating immune complexes in maternal sera and their relationship with parity and chronic villitis. *American journal of reproductive immunology and microbiology : AJRIM*. 1986; 12(1):4–6. Epub 1986/09/01. [PubMed: 3777310]
55. Johnston TA, Greer IA, Dawes J, Calder AA. Neutrophil activation in small for gestational age pregnancies. *British journal of obstetrics and gynaecology*. 1991; 98(1):105–6. Epub 1991/01/01. [PubMed: 1998619]
56. Kobayashi N, Yamada H, Kishida T, Kato EH, Ebina Y, Sakuragi N, et al. Hypocomplementemia correlates with intrauterine growth retardation in systemic lupus erythematosus. *Am J Reprod Immunol*. 1999; 42(3):153–9. Epub 1999/10/12. [PubMed: 10517175]
57. Sabatier F, Bretelle F, D'Ercole C, Boubli L, Sampol J, Dignat-George F. Neutrophil activation in preeclampsia and isolated intrauterine growth restriction. *American journal of obstetrics and gynecology*. 2000; 183(6):1558–63. Epub 2000/12/20. [PubMed: 11120528]
58. Johnson MR, Anim-Nyame N, Johnson P, Sooranna SR, Steer PJ. Does endothelial cell activation occur with intrauterine growth restriction? *BJOG : an international journal of obstetrics and gynaecology*. 2002; 109(7):836–9. Epub 2002/07/24. [PubMed: 12135223]
59. Coata G, Pennacchi L, Bini V, Liotta L, Di Renzo GC. Soluble adhesion molecules: marker of pre-eclampsia and intrauterine growth restriction. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2002; 12(1):28–34. Epub 2002/11/09.
60. Tjoa ML, van Vugt JM, Go AT, Blankenstein MA, Oudejans CB, van Wijk IJ. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. *Journal of reproductive immunology*. 2003; 59(1):29–37. Epub 2003/08/02. [PubMed: 12892901]
61. Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. *American journal of obstetrics and gynecology*. 2006; 194(5):1347–53. Epub 2006/05/02. [PubMed: 16647920]
62. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. *The Journal of experimental medicine*. 2006; 203(9):2165–75. Epub 2006/08/23. [PubMed: 16923853]
63. Laskowska M, Laskowska K, Leszczynska-Gorzela B, Oleszczuk J. Comparative analysis of the maternal and umbilical interleukin-8 levels in normal pregnancies and in pregnancies complicated by preeclampsia with intrauterine normal growth and intrauterine growth retardation. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2007; 20(7):527–32. Epub 2007/08/04.
64. Laskowska M, Laskowska K, Leszczynska-Gorzela B, Oleszczuk J. Maternal and umbilical sTNF-R1 in preeclamptic pregnancies with intrauterine normal and growth retarded fetus. *Hypertension in pregnancy : official journal of the International Society for the Study of Hypertension in Pregnancy*. 2007; 26(1):13–21. Epub 2007/04/25.
65. Erez O, Romero R, Hoppensteadt D, Than NG, Fareed J, Mazaki-Tovi S, et al. Tissue factor and its natural inhibitor in pre-eclampsia and SGA. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2008; 21(12):855–69. Epub 2008/12/10.
66. Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rotmensch S, et al. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. *American journal of obstetrics and gynecology*. 2002; 187(5):1137–42. Epub 2002/11/20. [PubMed: 12439491]
67. Kim YM, Bujold E, Chaiworapongsa T, Gomez R, Yoon BH, Thaler HT, et al. Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. *American journal of obstetrics and gynecology*. 2003; 189(4):1063–9. Epub 2003/10/31. [PubMed: 14586356]

68. Brosens I, Dixon HG, Robertson WB. Fetal growth retardation and the arteries of the placental bed. *British journal of obstetrics and gynaecology*. 1977; 84(9):656–63. Epub 1977/09/01. [PubMed: 911717]
69. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. *American journal of obstetrics and gynecology*. 1998; 179(6 Pt 1):1539–44. Epub 1998/12/17. [PubMed: 9855593]
70. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. *American journal of obstetrics and gynecology*. 2001; 184(6):1267–72. Epub 2001/05/12. [PubMed: 11349200]
71. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. *American journal of obstetrics and gynecology*. 2003; 188(1):177–82. Epub 2003/01/28. [PubMed: 12548214]
72. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. *British journal of obstetrics and gynaecology*. 1999; 106(10):1019–22. Epub 1999/10/16. [PubMed: 10519425]
73. Crispi F, Dominguez C, Llurba E, Martin-Gallan P, Cabero L, Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. *American journal of obstetrics and gynecology*. 2006; 195(1):201–7. Epub 2006/03/21. [PubMed: 16545329]
74. Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien JK, Goncalves L, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2008; 21(1):41–52. Epub 2008/01/05.
75. Garovic VD. The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension. *Hypertension*. 2012; 59(3):555–7. Epub 2012/02/09. [PubMed: 22311899]
76. Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Serum PLGF as a potential biomarker for predicting the onset of preeclampsia. *Archives of gynecology and obstetrics*. 2012; 285(2): 417–22. Epub 2011/07/08. [PubMed: 21735190]
77. Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. *Clinical chemistry*. 2012; 58(5): 837–45. Epub 2012/03/21. [PubMed: 22431894]
78. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. *Hypertension research : official journal of the Japanese Society of Hypertension*. 2010; 33(9):892–8. Epub 2010/06/11. [PubMed: 20535121]
79. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. *The New England journal of medicine*. 2004; 350(7):672–83. Epub 2004/02/07. [PubMed: 14764923]
80. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2005; 17(1):3–18. Epub 2005/04/05.
81. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2008; 21(1):9–23. Epub 2008/01/05.
82. Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia.

- American journal of obstetrics and gynecology. 2007; 197(2):176, e1–6. Epub 2007/08/11. [PubMed: 17689641]
83. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. *Hypertension*. 2005; 46(5):1077–85. Epub 2005/10/19. [PubMed: 16230516]
 84. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. *American journal of obstetrics and gynecology*. 2007; 197(3):244, e1–8. Epub 2007/09/11. [PubMed: 17826405]
 85. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2008; 21(5):279–87. Epub 2008/05/01.
 86. Unal ER, Robinson CJ, Johnson DD, Chang EY. Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. *American journal of obstetrics and gynecology*. 2007; 197(2):211, e1–4. Epub 2007/08/11. [PubMed: 17689655]
 87. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. *Obstetrics and gynecology*. 2007; 109(1):168–80. Epub 2007/01/02. [PubMed: 17197602]
 88. Park CW, Park JS, Shim SS, Jun JK, Yoon BH, Romero R. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. *American journal of obstetrics and gynecology*. 2005; 193(3 Pt 2):984–9. Epub 2005/09/15. [PubMed: 16157098]
 89. Chaiworapongsa T, Romero R, Tarca AL, Kusanovic JP, Gotsch F, Mittal P, et al. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. *American journal of obstetrics and gynecology*. 2010; 202(6):550, e1–10. Epub 2010/06/01. [PubMed: 20510958]
 90. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. *Young Investigator Award. American journal of obstetrics and gynecology*. 2004; 190(6):1541–7. discussion 7–50. Epub 2004/07/31.
 91. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *The Journal of clinical investigation*. 2003; 111(5):649–58. Epub 2003/03/06. [PubMed: 12618519]
 92. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. *The Journal of clinical endocrinology and metabolism*. 2003; 88(5):2348–51. Epub 2003/05/03. [PubMed: 12727995]
 93. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. *The Journal of clinical endocrinology and metabolism*. 2003; 88(11):5555–63. Epub 2003/11/07. [PubMed: 14602804]
 94. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nature medicine*. 2006; 12(6):642–9. Epub 2006/06/06.
 95. Bujold E, Romero R, Chaiworapongsa T, Kim YM, Kim GJ, Kim MR, et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2005; 18(1):9–16. Epub 2005/08/18.
 96. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. *Thrombosis research*. 2011; 127(Suppl 3):S72–5. Epub 2011/01/26. [PubMed: 21262447]

97. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. *American journal of obstetrics and gynecology*. 2010; 202(2):161, e1–e11. Epub 2009/10/24. [PubMed: 19850276]
98. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2011; 24(10):1187–207. Epub 2011/08/11.
99. Moore AG, Young H, Keller JM, Ojo LR, Yan J, Simas TA, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2012 Epub 2012/08/07.
100. Rana S, Cerdeira AS, Wenger J, Salahuddin S, Lim KH, Ralston SJ, et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. *PloS one*. 2012; 7(10):e48259. Epub 2012/10/31. [PubMed: 23110221]
101. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. *Circulation*. 2012; 125(7):911–9. Epub 2012/01/21. [PubMed: 22261192]
102. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007; 335(7627):974. Epub 2007/11/03. [PubMed: 17975258]
103. Jacquemyn Y, Jochems L, Duiker E, Bosmans JL, Van Hoof V, Van Campenhout C. Long-term renal function after HELLP syndrome. *Gynecologic and obstetric investigation*. 2004; 57(2):117–20. Epub 2004/01/07. [PubMed: 14707475]
104. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. *American journal of obstetrics and gynecology*. 1991; 165(5 Pt 1):1408–12. Epub 1991/11/01. [PubMed: 1957870]
105. Suzuki H, Watanabe Y, Arima H, Kobayashi K, Ohno Y, Kanno Y. Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. *Clinical and experimental nephrology*. 2008; 12(2):102–9. Epub 2008/01/09. [PubMed: 18180874]
106. Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxemia of pregnancy. *Heart*. 1997; 77(2):154–8. Epub 1997/02/01. [PubMed: 9068399]
107. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. *American heart journal*. 2008; 156(5):918–30. Epub 2008/12/09. [PubMed: 19061708]
108. Cassidy-Bushrow AE, Bielak LF, Rule AD, Sheedy PF, Turner ST, Garovic VD, et al. Hypertension during pregnancy is associated with coronary artery calcium independent of renal function. *J Womens Health (Larchmt)*. 2009; 18(10):1709–16. Epub 2009/09/30. [PubMed: 19785565]
109. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. *Hypertension*. 2009; 53(6):944–51. Epub 2009/05/13. [PubMed: 19433776]
110. Garovic VD, Bailey KR, Boerwinkle E, Hunt SC, Weder AB, Curb D, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. *Journal of hypertension*. 2010; 28(4):826–33. Epub 2010/01/21. [PubMed: 20087214]
111. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. *Hypertension*. 2010; 56(1):166–71. Epub 2010/06/03. [PubMed: 20516394]
112. Lin YS, Tang CH, Yang CY, Wu LS, Hung ST, Hwa HL, et al. Effect of pre-eclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan. *The American journal of cardiology*. 2011; 107(2):325–30. Epub 2011/01/08. [PubMed: 21211611]

113. Newstead J, von Dadelszen P, Magee LA. Preeclampsia and future cardiovascular risk. Expert review of cardiovascular therapy. 2007; 5(2):283–94. Epub 2007/03/07. [PubMed: 17338672]
114. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis. 2004; 175(2):189–202. Epub 2004/07/21. [PubMed: 15262174]
115. Potter JM, Nestel PJ. The hyperlipidemia of pregnancy in normal and complicated pregnancies. American journal of obstetrics and gynecology. 1979; 133(2):165–70. Epub 1979/01/15. [PubMed: 217273]
116. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet. 1994; 343(8898):645–6. Epub 1994/03/12. [PubMed: 7509433]
117. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in preeclampsia, are positively correlated, and decrease within 48 hours post partum. American journal of obstetrics and gynecology. 1996; 174(3):975–82. Epub 1996/03/01. [PubMed: 8633679]
118. Ogura K, Miyatake T, Fukui O, Nakamura T, Kameda T, Yoshino G. Low-density lipoprotein particle diameter in normal pregnancy and preeclampsia. Journal of atherosclerosis and thrombosis. 2002; 9(1):42–7. Epub 2002/09/20. [PubMed: 12238637]
119. Kaaja R, Tikkanen MJ, Viinikka L, Ylikorkala O. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. Obstetrics and gynecology. 1995; 85(3):353–6. Epub 1995/03/01. [PubMed: 7862371]
120. Hermes W, Van Kesteren F, De Groot CJ. Preeclampsia and cardiovascular risk. Minerva ginecologica. 2012; 64(4):281–92. Epub 2012/06/26. [PubMed: 22728573]
121. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension. 2007; 49(5):1056–62. Epub 2007/03/29. [PubMed: 17389257]
122. Kaaja R. Insulin resistance syndrome in preeclampsia. Seminars in reproductive endocrinology. 1998; 16(1):41–6. Epub 1998/07/09. [PubMed: 9654606]
123. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resistance in preeclampsia. Metabolism: clinical and experimental. 1999; 48(7):892–6. Epub 1999/07/27. [PubMed: 10421232]
124. Dietl J. Maternal obesity and complications during pregnancy. Journal of perinatal medicine. 2005; 33(2):100–5. Epub 2005/04/22. [PubMed: 15843256]
125. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM : monthly journal of the Association of Physicians. 2003; 96(11):793–807. Epub 2003/10/21. [PubMed: 14566035]
126. Black S, Kushner I, Samols D. C-reactive Protein. The Journal of biological chemistry. 2004; 279(47):48487–90. Epub 2004/09/01. [PubMed: 15337754]
127. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. The Journal of clinical investigation. 2003; 111(12):1805–12. Epub 2003/06/19. [PubMed: 12813013]
128. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102(18):2165–8. Epub 2000/11/01. [PubMed: 11056086]
129. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation. 2003; 108(16):1930–2. Epub 2003/10/08. [PubMed: 14530191]
130. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999; 145(2):375–9. Epub 1999/09/17. [PubMed: 10488966]
131. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006; 113(17):2128–34. discussion 51. Epub 2006/05/03. [PubMed: 16651484]
132. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006; 113(17):2135–50. discussion 50. Epub 2006/05/04. [PubMed: 16671184]

133. de Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. *The Journal of experimental medicine*. 1982; 156(1):230–42. Epub 1982/07/01. [PubMed: 7086355]
134. Pepys MB, Rowe IF, Baltz ML. C-reactive protein: binding to lipids and lipoproteins. *International review of experimental pathology*. 1985; 27:83–111. Epub 1985/01/01. [PubMed: 3915746]
135. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet*. 2010; 375(9709):132–40. Epub 2009/12/25. [PubMed: 20031199]
136. Correia M, Mendes S, Araujo C, Martins L, Bettencourt N, Leite D, et al. Subclavian steal syndrome in a coronary patient. *Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology*. 2011; 30(6):633–5. Epub 2011/08/31.
137. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *The New England journal of medicine*. 2004; 350(14):1387–97. Epub 2004/04/09. [PubMed: 15070788]
138. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation*. 1998; 98(8):731–3. Epub 1998/09/04. [PubMed: 9727541]
139. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP. C-reactive protein and myocardial infarction. *Journal of clinical epidemiology*. 2002; 55(5):445–51. Epub 2002/05/15. [PubMed: 12007546]
140. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. *Circulation*. 1999; 99(2):237–42. Epub 1999/01/20. [PubMed: 9892589]
141. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. *International journal of epidemiology*. 2006; 35(4):922–31. Epub 2006/03/28. [PubMed: 16565153]
142. Wilson PW, Nam BH, Pencina M, D'Agostino RB Sr, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. *Archives of internal medicine*. 2005; 165(21):2473–8. Epub 2005/11/30. [PubMed: 16314543]
143. Pearson TA, Mensah GA, Hong Y, Smith SC Jr. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: overview. *Circulation*. 2004; 110(25):e543–4. Epub 2004/12/22. [PubMed: 15611378]
144. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2010; 122(25):e584–636. Epub 2010/11/26. [PubMed: 21098428]
145. Madjid M, Willerson JT. Inflammatory markers in coronary heart disease. *British medical bulletin*. 2011; 100:23–38. Epub 2011/10/20. [PubMed: 22010105]
146. Correia LC, Esteves JP. C-Reactive protein and outcomes in acute coronary syndromes: a systematic review and meta-analysis. *Arquivos brasileiros de cardiologia*. 2011; 97(1):76–85. Epub 2011/09/08. [PubMed: 21897996]
147. Abd TT, Eapen DJ, Bajpai A, Goyal A, Dollar A, Sperling L. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. *Current atherosclerosis reports*. 2011; 13(2):154–61. Epub 2011/01/29. [PubMed: 21274757]
148. Rietzschel E, De Buyzere M. High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease? *Biomarkers in medicine*. 2012; 6(1):19–34. Epub 2012/02/03. [PubMed: 22296194]

149. Rebelo F, Schluskel MM, Vaz JS, Franco-Sena AB, Pinto TJ, Bastos FI, et al. C-reactive protein and later preeclampsia: systematic review and meta-analysis taking into account the weight status. *J Hypertens*. 2013; 31(1):16–26. Epub 2012/11/29. [PubMed: 23188419]
150. Garcia RG, Celedon J, Sierra-Laguado J, Alarcon MA, Luengas C, Silva F, et al. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. *American journal of hypertension*. 2007; 20(1):98–103. Epub 2007/01/03. [PubMed: 17198919]
151. Qiu C, Luthy DA, Zhang C, Walsh SW, Leisenring WM, Williams MA. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. *American journal of hypertension*. 2004; 17(2):154–60. Epub 2004/01/31. [PubMed: 14751658]
152. de Jonge LL, Steegers EA, Ernst GD, Lindemans J, Russcher H, Hofman A, et al. C-reactive protein levels, blood pressure and the risks of gestational hypertensive complications: the Generation R Study. *Journal of hypertension*. 2011; 29(12):2413–21. Epub 2011/10/18. [PubMed: 22002335]
153. Gandevani SB, Banaem LM, Mohamadi B, Moghadam NA, Asghari M. Association of high-sensitivity C-reactive protein serum levels in early pregnancy with the severity of preeclampsia and fetal birth weight. *Journal of perinatal medicine*. 2012; 0(0):1–5. Epub 2012/06/16. [PubMed: 22700647]
154. Kucukgoz Gulec U, Tuncay Ozgunen F, Baris Guzel A, Buyukurt S, Seydaoglu G, Ferhat Urunsak I, et al. An analysis of C-reactive protein, procalcitonin, and D-dimer in preeclamptic patients. *American journal of reproductive immunology*. 2012; 68(4):331–7. Epub 2012/07/13. [PubMed: 22783989]
155. Cemgil Arkan D, Aral M, Coskun A, Ozer A. Plasma IL-4, IL-8, IL-12, interferon-gamma and CRP levels in pregnant women with preeclampsia, and their relation with severity of disease and fetal birth weight. *J Matern Fetal Neonat*. 2012; 25(9):1569–73. Epub 2011/12/22.
156. Teran E, Escudero C, Calle A. C-reactive protein during normal pregnancy and preeclampsia. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2005; 89(3):299–300. Epub 2005/05/28.
157. Ertas IE, Kahyaoglu S, Yilmaz B, Ozel M, Sut N, Guven MA, et al. Association of maternal serum high sensitive C-reactive protein level with body mass index and severity of pre-eclampsia at third trimester. *The journal of obstetrics and gynaecology research*. 2010; 36(5):970–7. Epub 2010/08/21. [PubMed: 20722986]
158. Paternoster DM, Fantinato S, Stella A, Nanhorngue KN, Milani M, Plebani M, et al. C-reactive protein in hypertensive disorders in pregnancy. *Clin Appl Thromb Hemost*. 2006; 12(3):330–7. Epub 2006/09/09. [PubMed: 16959687]
159. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity*. 1995; 3(6):673–82. Epub 1995/12/01. [PubMed: 8777713]
160. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. *The Journal of biological chemistry*. 1996; 271(22):12687–90. Epub 1996/05/31. [PubMed: 8663110]
161. Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. *The Journal of biological chemistry*. 2008; 283(12):7754–62. Epub 2008/01/08. [PubMed: 18178561]
162. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattini G, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoïd production in primary human endothelial cells. *Circulation research*. 2003; 92(7):732–40. Epub 2003/03/22. [PubMed: 12649264]
163. Di Pietro R, Mariggio MA, Guarnieri S, Sancilio S, Giardinelli A, Di Silvestre S, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) regulates endothelial nitric oxide synthase (eNOS) activity and its localization within the human vein endothelial cells (HUVEC) in culture. *Journal of cellular biochemistry*. 2006; 97(4):782–94. Epub 2005/10/18. [PubMed: 16229016]

164. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. *Circulation*. 2003; 107(17):2250–6. Epub 2003/04/02. [PubMed: 12668516]
165. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. *Blood*. 2005; 105(9):3413–9. Epub 2005/01/13. [PubMed: 15644410]
166. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. *Journal of the American College of Cardiology*. 2005; 45(7):1018–24. Epub 2005/04/06. [PubMed: 15808757]
167. Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, et al. Acceleration of human neutrophil apoptosis by TRAIL. *J Immunol*. 2003; 170(2):1027–33. Epub 2003/01/09. [PubMed: 12517970]
168. Cziupka K, Busemann A, Partecke LI, Potschke C, Rath M, Traeger T, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) improves the innate immune response and enhances survival in murine polymicrobial sepsis. *Critical care medicine*. 2010; 38(11):2169–74. Epub 2010/07/27. [PubMed: 20657274]
169. McGrath EE, Marriott HM, Lawrie A, Francis SE, Sabroe I, Renshaw SA, et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. *Journal of leukocyte biology*. 2011; 90(5):855–65. Epub 2011/05/13. [PubMed: 21562052]
170. Deftereos S, Giannopoulos G, Kossyvakis C, Kaoukis A, Raisakis K, Panagopoulou V, et al. Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition. *Heart*. 2012; 98(3):214–8. Epub 2011/10/04. [PubMed: 21965221]
171. Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, et al. Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. *Atherosclerosis*. 2011; 215(2):452–8. Epub 2010/12/03. [PubMed: 21122855]
172. Mori K, Ikari Y, Jono S, Shioi A, Ishimura E, Emoto M, et al. Association of serum TRAIL level with coronary artery disease. *Thrombosis research*. 2010; 125(4):322–5. Epub 2009/12/26. [PubMed: 20034655]
173. Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. *PloS one*. 2009; 4(2):e4442. Epub 2009/02/18. [PubMed: 19221598]
174. Zauli G, Monasta L, Vecchi Brumatti L, Ronfani L, D'Ottavio G, Secchiero P. The early determination of circulating TRAIL levels does not predict the development of preeclampsia. *Placenta*. 2012; 33(2):135–6. Epub 2011/12/14. [PubMed: 22153912]
175. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. *American journal of obstetrics and gynecology*. 1997; 177(5):1003–10. Epub 1997/12/16. [PubMed: 9396883]
176. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. *Obstetrics and gynecology*. 1996; 87(2):163–8. Epub 1996/02/01. [PubMed: 8559516]
177. Seeds JW. Impaired fetal growth: definition and clinical diagnosis. *Obstetrics and gynecology*. 1984; 64(3):303–10. Epub 1984/09/01. [PubMed: 6379528]
178. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. *Science*. 1997; 276(5309):111–3. Epub 1997/04/04. [PubMed: 9082980]
179. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science*. 1997; 277(5327):815–8. Epub 1997/08/08. [PubMed: 9242610]
180. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. *FEBS letters*. 1997; 416(3):329–34. Epub 1997/12/31. [PubMed: 9373179]

181. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. *Immunity*. 1997; 7(6):821–30. Epub 1998/01/16. [PubMed: 9430227]
182. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science*. 1997; 277(5327):818–21. Epub 1997/08/08. [PubMed: 9242611]
183. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. *Nature cell biology*. 2000; 2(4):241–3. Epub 2000/04/27.
184. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. *Immunity*. 2000; 12(6):611–20. Epub 2000/07/14. [PubMed: 10894161]
185. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *The EMBO journal*. 1995; 14(22):5579–88. Epub 1995/11/15. [PubMed: 8521815]
186. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. *Immunity*. 2000; 12(6):599–609. Epub 2000/07/14. [PubMed: 10894160]
187. Bouillet P, Strasser A. BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. *Journal of cell science*. 2002; 115(Pt 8): 1567–74. Epub 2002/04/16. [PubMed: 11950875]
188. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell*. 1998; 94(4):491–501. Epub 1998/09/04. [PubMed: 9727492]
189. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. *The Journal of experimental medicine*. 1997; 186(7):1165–70. Epub 1997/10/07. [PubMed: 9314565]
190. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Current biology : CB*. 1997; 7(12):1003–6. Epub 1998/02/21. [PubMed: 9382840]
191. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell*. 1997; 89(2):309–19. Epub 1997/04/18. [PubMed: 9108485]
192. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. *The Journal of biological chemistry*. 1998; 273(23): 14363–7. Epub 1998/06/11. [PubMed: 9603945]
193. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U, et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. *Oncogene*. 2001; 20(30):4101–6. Epub 2001/08/09. [PubMed: 11494138]
194. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, et al. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. *Blood*. 2004; 103(10): 3837–44. Epub 2004/01/17. [PubMed: 14726404]
195. Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. *J Immunol*. 2000; 164(6):2897–904. Epub 2000/03/08. [PubMed: 10706675]
196. Chen L, Liu X, Zhu Y, Cao Y, Sun L, Jin B. Localization and variation of TRAIL and its receptors in human placenta during gestation. *Life sciences*. 2004; 74(12):1479–86. Epub 2004/01/20. [PubMed: 14729397]
197. Phillips TA, Ni J, Pan G, Ruben SM, Wei YF, Pace JL, et al. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. *J Immunol*. 1999; 162(10): 6053–9. Epub 1999/05/07. [PubMed: 10229846]

198. Keogh RJ, Harris LK, Freeman A, Baker PN, Aplin JD, Whitley GS, et al. Fetal-derived trophoblast use the apoptotic cytokine tumor necrosis factor- α -related apoptosis-inducing ligand to induce smooth muscle cell death. *Circulation research*. 2007; 100(6):834–41. Epub 2007/02/27. [PubMed: 17322170]
199. Whitley GS, Cartwright JE. Trophoblast-mediated spiral artery remodelling: a role for apoptosis. *Journal of anatomy*. 2009; 215(1):21–6. Epub 2009/02/14. [PubMed: 19215319]
200. Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, et al. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. *Arch Surg*. 1997; 132(12):1263–9. discussion 9–70. Epub 1997/12/24. [PubMed: 9403528]
201. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. *Circulation*. 2006; 114(14):1522–30. Epub 2006/09/27. [PubMed: 17000905]
202. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL--on a path to cancer immunotherapy. *Immunity*. 2003; 18(1):1–6. Epub 2003/01/18. [PubMed: 12530970]
203. Watt V, Chamberlain J, Steiner T, Francis S, Crossman D. TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. *Atherosclerosis*. 2011; 215(2):348–54. Epub 2011/02/18. [PubMed: 21324463]

Figure 1. Median plasma sTRAIL and CRP concentrations in women with uncomplicated pregnancy and preeclampsia

Women with preeclampsia had a significantly lower median (IQR) plasma sTRAIL concentration (pg/mL) than in those with uncomplicated pregnancy [25.55 (20.62–36.11) vs. 29.17 (25.24–36.28); $p = 0.03$]. For CRP, women with preeclampsia had a significantly higher median (IQR) plasma CRP concentration (ng/mL) than in those with uncomplicated pregnancy [8 (5.3–11.7) vs. 4.1 (1.2–8.6); $p = 0.001$].

Figure 2. Median plasma concentrations of sTRAIL and CRP in women with uncomplicated preterm gestations and preterm preeclampsia

Women with preterm preeclampsia had a significantly lower median (IQR) plasma concentration of sTRAIL (pg/mL) than in those with uncomplicated preterm gestations [24.76 (19.81–35.45) vs. 30.50 (26.41–39.23) pg/mL; $p = 0.03$]. For CRP, women with preterm preeclampsia had a significantly higher median (IQR) plasma concentration (ng/mL) than in those with uncomplicated preterm gestations [8.7 (5.5–19.7) vs. 4.1 (0.9–8.8); $p = 0.002$].

Figure 3. Median plasma concentrations of sTRAIL and CRP in women with uncomplicated term pregnancy and term preeclampsia

There was no significant difference in the median (IQR) plasma sTRAIL (pg/mL) and CRP (ng/mL) concentrations between these two groups [26.84 (22.95–33.45) vs. 23.82 (20.62–34.24); $p = 0.68$ and 4.9 (1.2–8.8) vs. 7.6 (3.4–10); $p = 0.32$, respectively].

Figure 4. The median plasma concentration of sTRAIL(pg/mL)/CRP(ng/mL) ratio in women with uncomplicated pregnancy and preeclampsia

Women with preeclampsia had a significantly lower median (IQR) plasma sTRAIL/CRP ratio than in those with uncomplicated pregnancy. [2.66 (1.63–5.1) vs. 5.89 (3.82–11.19); $p < 0.001$]. Plasma sTRAIL/CRP ratio could not be calculated in 7 patients who had CRP below the limit of detection.